Canada appeals court backs Pfizer Lipitor patent
NEW YORK (Reuters) - A Canadian appeals court has blocked the sale of a generic form of Pfizer Inc's (PFE.N: Quote) top-selling cholesterol fighter, Lipitor, by India's Ranbaxy Laboratories Ltd RANB.BO, overturning a lower court ruling, Pfizer said on Thursday.
The Federal Court of Appeal of Canada issued an order prohibiting approval of Ranbaxy's product in Canada until a Pfizer patent expires in July 2010, the company said.
The lower court had ruled that the enantiomer, or calcium salt, patent could not block Ranbaxy from seeking approval for a cheaper generic form of the world's biggest prescription medicine. Lipitor, known generically as atorvastatin calcium, has annual sales of about $12 billion.
Ranbaxy may seek a review of the decision by the Supreme Court of Canada, Pfizer said.
(Reporting by Bill Berkrot)
© Thomson Reuters 2017 All rights reserved.